Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory S Zaric

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 23, 2003
The impact of ignoring population heterogeneity when Markov models are used in cost-effectiveness analysisGregory S Zaric
Health Care Management Science|May 8, 2002
Random vs. nonrandom mixing in network epidemic modelsGregory S Zaric
Health Care Management Science|February 16, 2020
Welcome message from the new editorGregory S Zaric
Pharmacoeconomics|February 23, 2016
Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision MedicineGregory S Zaric
MDM Policy & Practice|February 24, 2021
How Risky Is That Risk Sharing Agreement? Mean-Variance Tradeoffs and Unintended Consequences of Six Common Risk Sharing AgreementsGregory S Zaric
Health Economics|January 12, 2008
Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progressionGregory S Zaric
Health Care Management Science|November 4, 2020
New developments for the journal in 2020Gregory S Zaric
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 7, 2014
Using price-volume agreements to manage pharmaceutical leakage and off-label promotionHui Zhang, Gregory S Zaric
Socio-Economic Planning Sciences|May 18, 2023
Healthcare Modeling ForewordGregory S Zaric, Arielle Lasry
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 4, 2009
The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefitsGregory S Zaric, Bin Xie
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Medical Decision Making : an International Journal of the Society for Medical Decision Making|October 23, 2003
The impact of ignoring population heterogeneity when Markov models are used in cost-effectiveness analysisGregory S Zaric
Health Care Management Science|May 8, 2002
Random vs. nonrandom mixing in network epidemic modelsGregory S Zaric
Health Care Management Science|February 16, 2020
Welcome message from the new editorGregory S Zaric
Pharmacoeconomics|February 23, 2016
Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision MedicineGregory S Zaric
MDM Policy & Practice|February 24, 2021
How Risky Is That Risk Sharing Agreement? Mean-Variance Tradeoffs and Unintended Consequences of Six Common Risk Sharing AgreementsGregory S Zaric
Health Economics|January 12, 2008
Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progressionGregory S Zaric
Health Care Management Science|November 4, 2020
New developments for the journal in 2020Gregory S Zaric
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 7, 2014
Using price-volume agreements to manage pharmaceutical leakage and off-label promotionHui Zhang, Gregory S Zaric
Socio-Economic Planning Sciences|May 18, 2023
Healthcare Modeling ForewordGregory S Zaric, Arielle Lasry
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 4, 2009
The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefitsGregory S Zaric, Bin Xie
Pageof 8